NME2 Antibody

What is NME2 and why is it important in cancer research?

NME2, also known as NM23-H2 or NDPK-B, is a multifunctional enzyme that plays crucial roles in controlling cell proliferation, differentiation, and apoptosis. This nucleoside diphosphate kinase is particularly important in cancer research due to its involvement in tumor progression and metastasis, making it a promising therapeutic target for cancer treatment. Studies have demonstrated that NME2 expression correlates with differentiation levels in gastric cancer cells and their lymph node metastasis patterns, suggesting its potential as a biomarker and therapeutic target . The protein functions by catalyzing the phosphorylation of nucleoside diphosphates to triphosphates and negatively regulates Rho activity through interaction with AKAP13/LBC. Additionally, NME2 acts as a transcriptional activator of the MYC gene, further connecting it to oncogenic processes .

What are the key differences between NME2 polyclonal and monoclonal antibodies?

NME2 antibodies are available in both polyclonal and monoclonal formats, each with distinct characteristics suitable for different research applications. Polyclonal antibodies, like the Rabbit Polyclonal Antibody (CAB7443), are produced in rabbits and recognize multiple epitopes on the NME2 protein, providing high sensitivity for detecting the target in various applications . These antibodies exhibit reactivity across human, mouse, and rat species, making them versatile for comparative studies.

Monoclonal antibodies, such as the mouse-derived Anti-human NME2 mAb (clone PAT5F4AT), recognize a single epitope with high specificity. These are developed through hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with NME2 . Monoclonal antibodies offer superior specificity and consistency between batches, making them ideal for quantitative research applications where reproducibility is critical.

What are the common synonyms and alternative names for NME2 in the scientific literature?

When searching literature or databases for NME2-related research, it's important to be aware of its multiple designations. NME2 is also known as:

• Nucleoside diphosphate kinase B (NDPK-B)

• NDPKB

• NM23-H2

• NM23B

• NDP kinase B

• C-myc purine-binding transcription factor PUF

• NDK B

• PUF

• MGC111212

Understanding these alternative nomenclatures is essential for comprehensive literature reviews and ensuring complete coverage when researching NME2-related topics.

What are the validated applications for NME2 antibodies in research protocols?

NME2 antibodies have been validated for multiple experimental applications, each requiring specific protocol optimizations:

• Western Blotting (WB): NME2 antibodies are effective at dilutions ranging from 1:500 to 1:2000, allowing researchers to detect NME2 protein expression levels in cell and tissue lysates .

• Immunohistochemistry-Paraffin (IHC-P): For tissue sections, NME2 antibodies perform optimally at dilutions between 1:50 and 1:200, enabling visualization of protein localization in fixed tissues .

• Enzyme-Linked Immunosorbent Assay (ELISA): NME2 antibodies can be utilized in ELISA protocols to quantify the protein in various samples .

• Immunofluorescence staining: As demonstrated in gastric cancer research, NME2 antibodies can be used at 1:100 dilution with FITC-conjugated secondary antibodies (1:100) for subcellular localization studies .

• Immunocytochemistry: Used for validating antibody staining patterns and assessing protein expression in selected human cell lines .

Each application requires specific optimization of antibody concentration, incubation conditions, and detection methods to achieve optimal signal-to-noise ratios.

How should researchers design immunofluorescence protocols for NME2 localization studies?

For optimal immunofluorescence staining of NME2, the following methodological approach is recommended:

• Cell preparation: Plate cells stably transfected with NME2 cDNA (and appropriate controls) on glass coverslips and allow them to grow to confluence.

• Fixation and permeabilization:

  • Rinse cells twice with ice-cold PBS

  • Fix with 4% paraformaldehyde in PBS for 15 minutes

  • Permeabilize with 0.5% Triton X-100

  • Block non-specific binding with 1% bovine serum albumin (BSA) for 30 minutes

• Antibody incubation:

  • Primary antibody: Apply anti-NME2 antibody (1:100 dilution in PBS containing 1% BSA) and incubate for 24 hours at 4°C

  • Secondary antibody: Incubate with FITC-conjugated secondary antibody (1:100 dilution) for 1 hour

• Nuclear counterstaining: Apply DAPI (1:100 in PBS) for 10 minutes at room temperature

• Imaging: Observe under a fluorescence microscope with appropriate filters for FITC and DAPI detection

This protocol allows precise visualization of NME2 subcellular localization, which is critical for understanding its function in normal and pathological conditions.

What are the recommended protocols for assessing NME2's impact on cell migration?

To evaluate NME2's effects on cell migration, researchers should employ complementary approaches:

• Wound-healing assay:

  • Plate cells in 6-well plates and grow to ≥95% confluence

  • Wash cells twice with PBS

  • Create 4-5 parallel scratches using a sterile pipette tip

  • Photograph the scratched tracks immediately

  • Incubate cells with 2.5 ml of serum-free DMEM medium

  • Document cell migration into the scratched area at 24-48 hour intervals

  • Calculate the reduction in cell-free area compared to baseline

• Transwell migration assay (for quantitative validation):

  • Plate 6×10^5 cells suspended in 500 μl serum-free medium containing 0.1% BSA in the upper chamber of a Transwell

  • Add 500 μl complete DMEM medium to the bottom chamber

  • Incubate for 24 hours to facilitate cell migration

  • Fix the membrane with 4% paraformaldehyde for 30 minutes

  • Stain transmigrated cells with 0.1% methyl violet for 30 minutes

  • Quantify migration by counting cells in 5 random fields (400× magnification)

Using both methods provides robust assessment of migration capabilities and helps validate findings through complementary approaches.

How can researchers optimize western blotting protocols for NME2 detection?

For optimal western blot detection of NME2 (17 kDa protein), consider these methodological optimizations:

• Sample preparation:

  • Use fresh samples whenever possible

  • Include protease inhibitors in lysis buffers

  • Determine optimal protein loading (typically 20-40 μg total protein)

  • Denature samples at 95°C for 5 minutes in reducing sample buffer

• Gel selection and transfer:

  • Use 12-15% polyacrylamide gels for optimal resolution of the 17 kDa NME2 protein

  • Transfer to PVDF membranes at 100V for 1 hour or 30V overnight at 4°C

  • Verify transfer efficiency with reversible protein stains

• Antibody incubation:

  • Block membranes with 5% non-fat milk or BSA for 1 hour at room temperature

  • Use NME2 primary antibody at 1:500-1:2000 dilution (optimize for each lot)

  • Incubate overnight at 4°C with gentle agitation

  • Perform extensive washing (4-5 times, 5 minutes each) with TBST

  • Use appropriate HRP-conjugated secondary antibody (typically 1:5000-1:10000)

• Signal development:

  • Use enhanced chemiluminescence substrates appropriate for expected expression levels

  • For weak signals, consider signal enhancement systems or longer exposure times

• Controls:

  • Include positive control lysates (cell lines known to express NME2)

  • Run size markers to confirm molecular weight

  • Consider including loading controls (β-actin, GAPDH) on the same membrane

This detailed approach minimizes background and ensures specific detection of NME2 protein.

What are the common pitfalls when using NME2 antibodies for IHC-P and how can they be addressed?

When performing immunohistochemistry on paraffin-embedded tissues (IHC-P) with NME2 antibodies, researchers should be aware of these common challenges and their solutions:

• Inconsistent staining:

  • Ensure uniform tissue fixation (10% neutral buffered formalin for 24-48 hours)

  • Standardize antigen retrieval methods (citrate buffer pH 6.0, 95-100°C for 20 minutes)

  • Use positive control tissues with known NME2 expression

  • Validate optimal antibody dilution (typically 1:50-1:200 for IHC-P)

• High background:

  • Increase blocking duration (5% normal serum from secondary antibody host species, 1 hour)

  • Extend washing steps (3-5 times, 5 minutes each)

  • Reduce primary antibody concentration

  • Pre-absorb secondary antibodies if necessary

• Weak or absent signal:

  • Optimize antigen retrieval conditions (test multiple methods)

  • Increase antibody concentration within recommended range

  • Extend primary antibody incubation (overnight at 4°C)

  • Use signal amplification systems (avidin-biotin complex, tyramine signal amplification)

• Non-specific binding:

  • Validate antibody specificity using knockout/knockdown controls

  • Perform blocking with endogenous peroxidase (3% H₂O₂, 10 minutes)

  • Include peptide competition controls

  • Use more stringent washing conditions

• Edge artifacts:

  • Prevent tissue drying during all protocol steps

  • Apply hydrophobic barrier around sections

  • Ensure adequate solution volume covers entire section

These optimizations improve staining consistency and reliability when detecting NME2 in tissue samples.

How should researchers validate the specificity of their NME2 antibody preparations?

Rigorous validation of NME2 antibody specificity is essential for reliable research outcomes. Implement the following comprehensive validation approaches:

• Genetic manipulation controls:

  • Compare staining between wild-type cells and NME2 knockdown/knockout models

  • Assess decrease in staining intensity upon target protein downregulation using siRNA

  • Evaluate staining in NME2-overexpressing cells versus controls

• Orthogonal technique validation:

  • Confirm protein detection using alternative methods (e.g., mass spectrometry)

  • Correlate antibody staining with mRNA expression data

  • Verify molecular weight by western blotting (17 kDa for NME2)

• Independent antibody comparison:

  • Compare staining patterns of two or more independent antibodies directed toward different epitopes of NME2

  • Assess concordance between monoclonal and polyclonal antibody staining patterns

• Tagged protein comparison:

  • Evaluate signal overlap between antibody staining and GFP-tagged NME2 protein

  • Confirm colocalization using confocal microscopy

• Cross-reactivity assessment:

  • Test antibody against closely related proteins (especially NME1, which shares high sequence homology)

  • Perform peptide competition assays

  • Check for staining in tissues known to lack NME2 expression

These validation steps ensure that experimental observations truly reflect NME2 biology rather than artifacts of non-specific antibody reactivity.

How can NME2 antibodies be employed to study its role in tumor metastasis suppression?

For investigating NME2's metastasis suppression functions, researchers can employ these advanced approaches:

• Comparative expression analysis:

  • Utilize NME2 antibodies for IHC staining across primary tumors and matched metastatic lesions

  • Correlate expression levels with clinical outcomes and metastatic potential

  • Implement tissue microarray approaches for high-throughput analysis

• Protein complex identification:

  • Perform co-immunoprecipitation using NME2 antibodies to identify interacting partners in metastatic vs. non-metastatic cells

  • Couple with mass spectrometry to map the NME2 interactome

  • Validate interactions through reverse co-IP and proximity ligation assays

• Functional domain mapping:

  • Generate domain-specific antibodies to distinguish between NME2's kinase activity and transcriptional functions

  • Use phospho-specific antibodies to assess NME2's phosphorylation state in different cellular contexts

  • Correlate post-translational modifications with metastatic behavior

• In vivo metastasis models:

  • Track NME2 expression during metastatic progression using antibody-based imaging

  • Compare experimental metastasis between NME2-overexpressing and control cells

  • Assess spontaneous metastasis formation in orthotopic models with modulated NME2 expression

• Therapeutic targeting assessment:

  • Monitor NME2 expression as a biomarker for response to anti-metastatic therapies

  • Evaluate antibody-drug conjugates targeting NME2-expressing cells

  • Develop approaches to modulate NME2 activity in metastasis-prone cells

These advanced applications leverage NME2 antibodies to elucidate mechanisms underlying its metastasis suppression functions and develop potential therapeutic strategies .

What are the key considerations when investigating NME2 and its interaction with transcriptional regulation pathways?

NME2 functions as a transcriptional activator of the MYC gene and interacts with various regulatory pathways. When investigating these interactions:

• Chromatin immunoprecipitation (ChIP) approaches:

  • Use highly specific NME2 antibodies for ChIP to identify genomic binding sites

  • Couple with sequencing (ChIP-seq) to map genome-wide binding profiles

  • Validate binding through reporter assays and directed mutagenesis

  • Optimize crosslinking conditions for transient DNA-protein interactions

• Transcription factor complex analysis:

  • Perform sequential ChIP (re-ChIP) to identify co-binding factors

  • Use size-exclusion chromatography followed by immunoblotting to identify NME2-containing complexes

  • Assess NME2 binding to non-specific DNA sequences and its functional significance

  • Investigate interaction with MYC promoter elements

• Kinase-transcription factor relationships:

  • Distinguish between NME2's enzymatic (kinase) and DNA-binding activities

  • Investigate how phosphorylation of transcription factors by NME2 affects their function

  • Analyze how NME2's nucleoside diphosphate kinase activity influences transcriptional outcomes

  • Develop assays to measure localized nucleotide concentrations at promoter regions

• Subcellular localization dynamics:

  • Track nuclear-cytoplasmic shuttling of NME2 under different cellular conditions

  • Identify signals that promote nuclear accumulation

  • Correlate subcellular localization with transcriptional activity

  • Use fluorescently tagged antibodies for live-cell imaging of NME2 dynamics

These approaches help elucidate NME2's dual roles as both an enzyme and a transcriptional regulator, providing insights into its complex functions in normal and pathological states .

How can researchers harness NME2 antibodies for studying its role in cell cycle regulation and apoptosis?

To investigate NME2's functions in cell cycle control and apoptosis:

• Cell cycle analysis protocols:

  • Synchronize cells at different cell cycle phases

  • Collect and fix cells with 70% ice-cold ethanol at 4°C for 24 hours

  • Wash twice with ice-cold PBS

  • Treat with RNase A (20 μg/ml) for 30 minutes at 37°C

  • Incubate with propidium iodide (10 μg/ml) in the dark for 30 minutes

  • Analyze by flow cytometry for DNA content and cell cycle distribution

  • Correlate NME2 expression levels with cell cycle phase using dual staining approaches

• Apoptosis investigation methods:

  • Detect apoptotic markers (cleaved caspases, PARP cleavage) in relation to NME2 expression

  • Perform Annexin V/PI staining in cells with modulated NME2 levels

  • Analyze mitochondrial membrane potential changes and cytochrome c release

  • Correlate NME2 subcellular redistribution with initiation of apoptotic signaling

• Cell synchronization approaches:

  • Use double thymidine block, nocodazole, or serum starvation methods to synchronize cells

  • Monitor NME2 expression and localization throughout cell cycle progression

  • Assess NME2 phosphorylation status at different cell cycle checkpoints

  • Implement FUCCI (fluorescent ubiquitination-based cell cycle indicator) systems for live imaging

• Signaling pathway analysis:

  • Investigate NME2 interaction with key cell cycle regulators (cyclins, CDKs)

  • Assess impact on p53 pathways and DNA damage responses

  • Explore connections to survival signaling (PI3K/Akt, MAPK pathways)

  • Analyze feedback loops between NME2 and cell cycle checkpoints

These methodologies provide a comprehensive framework for elucidating NME2's roles in determining cell fate decisions between proliferation, arrest, and apoptosis .

How should researchers reconcile contradictory findings about NME2's role in different cancer types?

NME2 exhibits context-dependent functions that vary across cancer types, necessitating careful data interpretation:

• Tissue-specific expression patterns:

  • Compare NME2 expression across tissue types using antibody-based tissue microarrays

  • Normalize expression to appropriate tissue-specific controls

  • Consider developmental lineage influences on NME2 function

  • Analyze splice variant expression that may affect antibody recognition

• Methodological standardization:

  • Document antibody clone, dilution, and validation methods

  • Specify cell lines and their authentication status

  • Detail experimental conditions that may influence outcomes

  • Ensure appropriate statistical analyses for sample size

• Multifunctional protein analysis:

  • Distinguish between NME2's enzymatic functions and transcriptional regulatory roles

  • Assess whether contradictions stem from different functional domains

  • Investigate protein interactions specific to each cancer type

  • Consider post-translational modifications that may alter function

• Genetic background considerations:

  • Evaluate how host genetic factors influence NME2 activity

  • Assess patterns in relation to common oncogenic drivers (KRAS, p53, etc.)

  • Consider chromosomal context and gene dosage effects

  • Analyze epigenetic regulation across cancer types

• Reconciliation strategies:

  • Perform meta-analyses of published findings with standardized criteria

  • Design experiments that directly test contradictory hypotheses

  • Develop unified models that accommodate context-dependent functions

  • Implement systems biology approaches to map network-level influences

These approaches help resolve apparent contradictions and develop nuanced understanding of NME2's complex roles in cancer biology .

What technical considerations impact the interpretation of NME2 antibody-based experimental results?

When analyzing data generated using NME2 antibodies, researchers should consider these technical factors:

• Antibody specificity limitations:

  • Acknowledge potential cross-reactivity with the highly homologous NME1 protein

  • Consider the specific epitope recognized and whether it might be masked in certain contexts

  • Evaluate whether post-translational modifications affect antibody binding

  • Assess whether antibody recognizes all relevant isoforms

• Detection method constraints:

  • Recognize sensitivity thresholds of various detection methods

  • Account for signal saturation in highly expressing samples

  • Consider linear dynamic range limitations in quantitative analyses

  • Acknowledge that different secondary detection systems may yield varying results

• Sample preparation variables:

  • Evaluate how fixation affects epitope accessibility in IHC/ICC

  • Consider how sample processing might denature or modify the antigen

  • Assess buffer compatibility with maintaining protein conformation

  • Document pre-analytical variables that could impact results

• Quantification challenges:

  • Standardize scoring methods for immunohistochemistry

  • Implement appropriate controls for normalization

  • Use digital image analysis when possible for objective quantification

  • Consider the impact of heterogeneous expression within samples

• Validation approaches:

  • Correlate antibody-based results with orthogonal methods (qPCR, mass spectrometry)

  • Include biological replicates to account for natural variation

  • Employ multiple antibodies targeting different epitopes

  • Consider genetic approaches (CRISPR/siRNA) to validate specificity

Addressing these technical considerations enhances the reliability and reproducibility of NME2 antibody-based research findings.

How can researchers design experiments to differentiate between NME1 and NME2 functions despite their high sequence homology?

Distinguishing the specific functions of NME1 and NME2 presents challenges due to their 88% sequence identity. Implement these specialized approaches:

• Selective antibody validation:

  • Perform extensive cross-reactivity testing against recombinant NME1 and NME2

  • Map epitopes to regions of sequence divergence

  • Validate using knockout/knockdown models of each protein

  • Pre-absorb antibodies with the non-target protein to enhance specificity

• Genetic manipulation strategies:

  • Design siRNAs targeting unique 3'UTR regions

  • Implement isoform-specific CRISPR-Cas9 targeting

  • Use rescue experiments with mutated constructs resistant to siRNA

  • Develop conditional knockout models specific to each gene

• Protein-specific interaction mapping:

  • Perform tandem affinity purification with isoform-specific tags

  • Identify differential binding partners through mass spectrometry

  • Validate interactions using proximity ligation assays

  • Develop interactome maps specific to each protein

• Functional assays with isoform specificity:

  • Assess unique functions (NME2's role as transcription factor vs. NME1)

  • Design biochemical assays that can distinguish between the proteins

  • Measure enzymatic activities under conditions that differentially affect each isoform

  • Analyze subcellular localization patterns unique to each protein

• Computational approaches:

  • Implement molecular dynamics simulations to identify functional differences

  • Analyze evolutionary conservation patterns in non-homologous regions

  • Predict differential post-translational modifications

  • Model protein-protein interactions based on structural differences

These methodological approaches allow researchers to delineate the unique functions of these highly similar but functionally distinct proteins in normal physiology and disease states.

What emerging technologies might enhance the utility of NME2 antibodies in cancer research?

Advanced technological approaches are poised to expand NME2 antibody applications:

• Single-cell protein profiling:

  • Apply NME2 antibodies in mass cytometry (CyTOF) for high-dimensional analysis

  • Implement single-cell western blotting to assess expression heterogeneity

  • Develop multiplex immunofluorescence panels including NME2 and its interactors

  • Integrate with single-cell transcriptomics for multi-omic analysis

• In situ protein interaction mapping:

  • Apply proximity ligation assays to visualize NME2 interactions in intact tissues

  • Implement FRET/FLIM approaches with fluorescently labeled antibodies

  • Develop split-reporter systems for detecting dynamic interactions

  • Apply advanced microscopy techniques for super-resolution imaging of NME2 complexes

• Therapeutic targeting approaches:

  • Develop antibody-drug conjugates targeting NME2 in cancer cells

  • Engineer bispecific antibodies linking NME2 to immune effector cells

  • Create nanobody-based imaging agents for tumor detection

  • Design intrabodies to modulate NME2 function in specific cellular compartments

• Structure-guided approaches:

  • Generate conformation-specific antibodies recognizing active vs. inactive NME2

  • Develop antibodies targeting specific functional domains

  • Create tools for detecting oligomerization states

  • Design antibody fragments for intracellular delivery

These emerging technologies will expand our understanding of NME2's roles in cancer biology and potentially lead to novel diagnostic and therapeutic applications.

How might NME2 antibody-based research contribute to personalized cancer medicine approaches?

NME2 research shows significant potential for advancing precision oncology:

• Predictive biomarker development:

  • Standardize NME2 immunohistochemistry scoring for clinical application

  • Correlate expression patterns with treatment responses

  • Develop companion diagnostics for emerging targeted therapies

  • Integrate with multi-biomarker panels for enhanced predictive power

• Patient stratification approaches:

  • Identify patient subgroups based on NME2 expression patterns

  • Correlate NME2 status with metastatic potential

  • Develop algorithms integrating NME2 with other molecular markers

  • Establish prognostic models incorporating NME2 expression

• Therapeutic resistance mechanisms:

  • Monitor NME2 expression changes during treatment

  • Investigate correlation between NME2 and drug efflux pathways

  • Assess relationship to cancer stem cell phenotypes

  • Evaluate potential as a target for overcoming resistance

• Minimal residual disease detection:

  • Develop sensitive assays for detecting NME2-expressing circulating tumor cells

  • Create protocols for monitoring treatment response

  • Establish thresholds for clinical decision-making

  • Integrate with liquid biopsy approaches